Trial Profile
A Phase II Trial of MGI 114 in Patients With Advanced Pancreatic Adenocarcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 May 2022
Price :
$35
*
At a glance
- Drugs Irofulven (Primary)
- Indications Pancreatic cancer
- Focus Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 17 Sep 2005 New trial record.